The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I/II dose-escalation study of fractionated and multiple dose 225Ac-J591 for progressive metastatic castration-resistant prostate cancer (mCRPC).
 
Michael Sun
No Relationships to Disclose
 
Jones T. Nauseef
No Relationships to Disclose
 
Justin M Lebenthal
No Relationships to Disclose
 
Muhammad Junaid Niaz
Stock and Other Ownership Interests - Actinium Pharmaceuticals; Axovant Sciences
Travel, Accommodations, Expenses - Endocyte
 
Sharon Singh
No Relationships to Disclose
 
Tessa A Chamberlain
No Relationships to Disclose
 
Mahelia Bissassar
No Relationships to Disclose
 
Amie Patel
No Relationships to Disclose
 
Angela Tan
No Relationships to Disclose
 
Shankar Vallabhajosula
Employment - NCM-USA
Leadership - NCM-USA
Stock and Other Ownership Interests - NCM-USA
 
John Babich
No Relationships to Disclose
 
Paul J. Christos
No Relationships to Disclose
 
Joseph Osborne
No Relationships to Disclose
 
Ana M. Molina
Honoraria - ASCO
Consulting or Advisory Role - Eisai; Eisai; Eisai; Exelixis; Janssen
 
Cora N. Sternberg
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Genzyme; Immunomedics; Incyte; Medscape; Merck; MSD; Pfizer; Roche; UroToday
 
David M. Nanus
Consulting or Advisory Role - Roche/Genentech
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); Immumedics (Inst); Janssen (Inst); Novartis (Inst); pfizer (Inst); Zenith Epigenetics (Inst)
 
Neil Harrison Bander
Stock and Other Ownership Interests - BZL Biologics; Telix Pharmaceuticals
Consulting or Advisory Role - ADC Therapeutics; BZL Biologics; Tarveda Therapeutics; Telix Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Patents to anti-PSMA antibodies assigned to Cornell Univ; Royalty--Cook Urological
 
Scott T. Tagawa
Consulting or Advisory Role - Abbvie; Amgen; Astellas Pharma; Bayer; Blue Earth Diagnostics; Clovis Oncology; Dendreon; Endocyte; Genentech; Genomic Health; Immunomedics; Janssen; Karyopharm Therapeutics; Medivation; Novartis; Pfizer; POINT Biopharma; QED Therapeutics; Sanofi; Tolmar
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Dendreon (Inst); Endocyte (Inst); Exelixis (Inst); Genentech (Inst); Immunomedics (Inst); Inovio Pharmaceuticals (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Newlink Genetics (Inst); Novartis (Inst); Progenics (Inst); Rexahn Pharmaceuticals (Inst); Sanofi (Inst); Stem CentRx (Inst)
Travel, Accommodations, Expenses - Amgen; Immunomedics; Sanofi
(OPTIONAL) Uncompensated Relationships - ATLAB Pharma; Phosplatin Therapeutics; Telix Pharmaceuticals